发明授权
- 专利标题: Vitronectin receptor antagonist pharmaceuticals
- 专利标题(中): Vitronectin受体拮抗剂药物
-
申请号: US09599890申请日: 2000-06-21
-
公开(公告)号: US07332149B1公开(公告)日: 2008-02-19
- 发明人: Milind Rajopadhye , John A. Barrett , Alan P. Carpenter, Jr. , Edward H. Cheesman , Thomas D. Harris
- 申请人: Milind Rajopadhye , John A. Barrett , Alan P. Carpenter, Jr. , Edward H. Cheesman , Thomas D. Harris
- 申请人地址: US NJ Princeton
- 专利权人: Bristol-Myers Squibb Pharma Company
- 当前专利权人: Bristol-Myers Squibb Pharma Company
- 当前专利权人地址: US NJ Princeton
- 代理机构: Woodcock Washburn LLP
- 代理商 Jennifer C. Chapman; John F. Levis
- 主分类号: A61K51/00
- IPC分类号: A61K51/00 ; A61K51/04 ; A61K51/06 ; A61M36/00 ; A61P35/00 ; C07D231/54 ; C07D259/00 ; C07D403/14 ; A61K31/416 ; A61K31/33
摘要:
The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
信息查询